Friedman Center for Nutrition & Inflammation
Found 150 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2022
Viladomiu M, Khounlotham M, Dogan B, Lima SF, Elsaadi A, Cardakli E, Castellanos JG, Ng C, Herzog J, Schoenborn AA et al..  2022.  Agr2-associated ER stress promotes adherent-invasive E. coli dysbiosis and triggers CD103+ dendritic cell IL-23-dependent ileocolitis.. Cell Rep. 41(7):111637.
Viladomiu M, Khounlotham M, Dogan B, Lima SF, Elsaadi A, Cardakli E, Castellanos JG, Ng C, Herzog J, Schoenborn AA et al..  2022.  Agr2-associated ER stress promotes adherent-invasive E. coli dysbiosis and triggers CD103+ dendritic cell IL-23-dependent ileocolitis.. Cell Rep. 41(7):111637.
Skovsø S, Panzhinskiy E, Kolic J, Cen HHoward, Dionne DA, Dai X-Q, Sharma RB, Elghazi L, Ellis CE, Faulkner K et al..  2022.  Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.. Nat Commun. 13(1):735.
Skovsø S, Panzhinskiy E, Kolic J, Cen HHoward, Dionne DA, Dai X-Q, Sharma RB, Elghazi L, Ellis CE, Faulkner K et al..  2022.  Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.. Nat Commun. 13(1):735.
Skovsø S, Panzhinskiy E, Kolic J, Cen HHoward, Dionne DA, Dai X-Q, Sharma RB, Elghazi L, Ellis CE, Faulkner K et al..  2022.  Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.. Nat Commun. 13(1):735.
Skovsø S, Panzhinskiy E, Kolic J, Cen HHoward, Dionne DA, Dai X-Q, Sharma RB, Elghazi L, Ellis CE, Faulkner K et al..  2022.  Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.. Nat Commun. 13(1):735.
Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R.  2022.  Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.. Clin Gastroenterol Hepatol. 20(3):e361-e379.
Nwosu BUdoka, Parajuli S, Jasmin G, Fleshman J, Sharma RB, Alonso LC, Lee AF, Barton BA.  2022.  Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial.. J Endocr Soc. 6(1):bvab179.
Jin W-B, Li T-T, Huo D, Qu S, Li XV, Arifuzzaman M, Lima SF, Shi H-Q, Wang A, Putzel GG et al..  2022.  Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome.. Cell. 185(3):547-562.e22.
Zhou L, Zhou W, Joseph AM, Chu C, Putzel GG, Fang B, Teng F, Lyu M, Yano H, Andreasson KI et al..  2022.  Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation.. Nat Immunol. 23(2):251-261.
Burnham P, Chen F, Cheng AP, Srivatana V, Zhang LT, Edusei E, Albakry S, Botticelli B, Guo X, Renaghan A et al..  2022.  Peritoneal Effluent Cell-Free DNA Sequencing in Peritoneal Dialysis Patients With and Without Peritonitis.. Kidney Med. 4(1):100383.
Burnham P, Chen F, Cheng AP, Srivatana V, Zhang LT, Edusei E, Albakry S, Botticelli B, Guo X, Renaghan A et al..  2022.  Peritoneal Effluent Cell-Free DNA Sequencing in Peritoneal Dialysis Patients With and Without Peritonitis.. Kidney Med. 4(1):100383.
Battat R, Galati JS, Lukin D, Chabouni F, Sockolow R, Carter J, Fajardo K, Yang S, Reich J, Jacobs V et al..  2022.  A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease.. J Clin Gastroenterol. 56(3):e176-e182.
Battat R, Galati JS, Lukin D, Chabouni F, Sockolow R, Carter J, Fajardo K, Yang S, Reich J, Jacobs V et al..  2022.  A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease.. J Clin Gastroenterol. 56(3):e176-e182.
Battat R, Galati JS, Lukin D, Chabouni F, Sockolow R, Carter J, Fajardo K, Yang S, Reich J, Jacobs V et al..  2022.  A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease.. J Clin Gastroenterol. 56(3):e176-e182.
Battat R, Galati JS, Lukin D, Chabouni F, Sockolow R, Carter J, Fajardo K, Yang S, Reich J, Jacobs V et al..  2022.  A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease.. J Clin Gastroenterol. 56(3):e176-e182.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2022.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell. 29(1):101-115.e10.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2022.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell. 29(1):101-115.e10.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2022.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell. 29(1):101-115.e10.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2022.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell. 29(1):101-115.e10.
Lima SF, Gogokhia L, Viladomiu M, Chou L, Putzel G, Jin W-B, Pires S, Guo C-J, Gerardin Y, Crawford CV et al..  2022.  Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.. Gastroenterology. 162(1):166-178.
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP et al..  2022.  Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 7(1):69-95.
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP et al..  2022.  Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 7(1):69-95.
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP et al..  2022.  Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 7(1):69-95.
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP et al..  2022.  Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 7(1):69-95.